netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
News Title

19th May 2020

Flu Season Has Ended- Please see details Here

Guidance documents can be found here for out of season influenza prescribing. Alternatively search the term "FLUOOS" in the search bar.


Ibuprofen and coronavirus (COVID-19)

The Commission of Human Medicines (CHM) has been asked to review the safety of ibuprofen in patients with COVID-19. The Commission on Human Medicines’ Expert Working Group on coronavirus (COVID-19) has concluded that there is currently insufficient evidence to establish a link between use of ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), and contracting or worsening of COVID-19.

Patients can take paracetamol or ibuprofen when self-medicating for symptoms of COVID-19, such as fever and headache, and should follow NHS advice if they have any questions or if symptoms get worse.

For full details see here.


Class 2 Drug Alert: Emerade 300mcg pre-filled syringe - patient level recall

Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerade 300 microgram auto-injectors (also referred to as pens) from patients due to an error in one component of the auto-injector believed to cause some pens to fail to activate and deliver adrenaline.  The full alert is available here. 
Healthcare professionals (GP Practices, Pharmacies) should contact patients and carers with Emerade 300mcg pens, to inform them of the recall information contained within this alert. Additional advice has also been provided for patients with Emerade 500mcg pens, which are not currently subject to a recall due to insufficient supplies of alternative brands of pens. 
No further supplies of Emerade will be available on the UK market until the issue has been resolved, therefore patients and carers should be appropriately trained to use other brands.

Class 2 Medicines Recall: Esmya 5mg tablets, EU/1/12/750/001-5, (EL(20)A/16)

See full drug alert here

Gedeon Richter (UK) Ltd is recalling all unexpired stock of Esmya 5 mg tablets from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine.

Advice for healthcare professionals

Contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should contact their doctor for advice about other possible treatments for uterine fibroids.

Stop supplying the above products immediately and remove from the shelves within your store. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Stop prescribing Esmya or generic ulipristal acetate for the treatment of uterine fibroids. No new patients should start treatment with the medicines, which has been suspended throughout the EU during the review. Consider other treatment options as appropriate.

Liver function testing should be performed 2- 4 weeks after treatment has stopped as described in the product information for the medicines.

Healthcare professionals should alert patients to immediately report signs and symptoms of liver injury (such as nausea, vomiting, right hypochondrial pain, anorexia, asthenia, jaundice) which could occur after stopping treatment.


Class 2 Medicines Recall: LEO Laboratories Ltd, Picato 150 mcg/g gel

See full drug alert here

LEO Laboratories Ltd (T/A LEO Pharma) is recalling all unexpired stock of the above products from pharmacies and wholesalers as a precautionary measure due to concerns on the possible risk of skin malignancy. The recall is a precautionary measure following the suspension of the marketing authorisation of Picato (ingenol mebutate), while investigations are ongoing.

Advice for healthcare professionals

  • Stop supplying the above products immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

  • Stop prescribing Picato and consider other treatment options as appropriate. For patients who have recently been prescribed Picato, advise patients to be vigilant for any skin lesions developing and to seek medical advice promptly should any occur.



Magnesium Hydroxide Mixture Shortage

Due to difficulties obtaining raw materials, there are currently no stocks of magnesium hydroxide mixture. The earliest anticipated return date is Feb 2020. Alternative laxatives will be required in the interim (lactulose and macrogol being alternative osmotic laxatives). 


03/12/2019 - We are now in Flu Season 

Surveillance data indicates an increase in influenza cases in the community. Prescribers may now prescribe and pharmacists may now supply antiviral medicines for the prophylaxis and treatment of influenza at NHS expense.  

Please see here for further information 


Shortages update - 28th October

Opicapone 50mg capsules will be out of stock from mid-November to mid-January 2020 - see CAS alert for details.

Fluoxetine 10mg capsules are now available therefore the SSP has been withdrawn.  The SSPs for 30mg and 40mg capsules are still in place.

Paroxetine oral solution is out of stock from the end of October to January 2020.  Unlicensed imports are available; the tablets can also be crushed and mixed with water (note this is off-label and the tablets are bitter with slight local anaesthetic effects).


Nifedipine 5mg and 10mg capsules

Adalat brand was discontinued earlier in the year.

Generic brand is now available from Relonchem


16th October - Ranitidine supply issue 

  • All oral formulations of ranitidine are anticipated to be out of stock, with no date for resupply until further notice.

  • An investigation by the Swiss and German regulatory agencies and the US Food and Drug Administration (FDA), has identified a contaminant, N-nitrosodimethylamine (NDMA), in samples of ranitidine active substance.

  • All stock manufactured for the UK using the affected ranitidine active substance has been quarantined, whilst Medicines and Healthcare products Regulatory Agency (MHRA) investigations are ongoing.
  • Although all oral formulations are expected to be out of stock, very limited supplies of unaffected oral ranitidine products may remain available and should be reserved for those patients in whom alternatives are not clinically appropriate.
  • All other patients should be reviewed as repeat prescriptions are requested, and if ongoing treatment is required, be switched to clinical alternatives.
  • Please see the CAS alert for details about actions required and alternatives

14th October 2019 - Updates to shortages

Phenelzine now unavailable until March 2020 (see drug entry for details)

Adrenaline auto-injectors

  • Emerade supplies expected w/c 14th October
  • Reports of Emerade auto-injectors failing to activate, patients must carry two pens at all times
  • Some batches of EpiPen and Jext have had their expiry dates extended - see and for details
  • Further details can be found here (N3 connection required)

11th October

Serious shortage protocols for fluoxetine

Serious shortage protocols are available for use with the fluoxetine capsule shortage see here.



UPDATE: Ranitidine products linked to impurity and carcinogen (NDMA).

Zantac – MHRA drug alert issued as GlaxoSmithKline recalls all unexpired pharmacy stock.

At present patients and healthcare professionals are advised to continue using their medicines as normal. The health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. Currently there is no evidence that medicines containing the impurity have caused any harm to patients but the MHRA is closely monitoring the situation. Patients do not need to see their Doctor until their next routine appointment, but should seek their doctor’s advice if they have any concerns.

An MHRA investigation into other brands of ranitidine medicines which may also be affected is continuing and further updates will be provided as this investigation progresses. Currently other ranitidine products have not been recalled.


Shortages update 30th September 2019

  • Loestrin 20 and 30 have been discontinued by the manufacturer
  • Noriday is now back in stock
  • EpiPen Junior is now subject to prescription validation process

Shortage update 24th September 2019 - manufacturing delays

Both strengths of capsaicain cream will be out of stock until at least November 2019. For more information click here (commercially sensitive, N3 connection only)

Both strengths of mianserin are out of stock until the end of 2019. For more information click here (commercially sensitive, N3 connection only). 

All strengths of tiagabine will be out of stock until the end of October 2019. For more information click here (commercially sensitive, N3 connection only). 


Shortage update 23rd September 2019

Due to manufacturing delays, medroxyprogesterone acetate 100mg tablets are out of stock until w/e 8th November 2019 (200mg and 400mg tablets remain available). Click here for more information/advice (commercially sensitive, N3 connection only).

There is currently a supply issue affecting fluoxetine 10mg, 30mg and 40mg capsules due to manufacturing issues, and stocks are not expected to be available until early December 2019. Click here for more information/advice (commercially sensitive, N3 connection only).



Shortage update

Phenytoin suspension shortage has now resolved. 

Mianserin tablets out of stock until the end of 2019, unlicensed imports are available.

Tiagabine tablets due to be out of stock until end of October 2019 once limited remaining stock exhausted.  Please review which patients are likely to have insufficient supplies to last and order unlicensed imports as necessary.  For patients who unlicensed supplies are not appropriate, please refer to secondary care for review.

Capsaicin 0.075% and 0.025% cream are both out of stock until at least November 2019.  Please see SPS guidance for details.


Shortage of progestogen only contraceptive pills

6th September 2019

There is a current shortage of Noriday and Norgeston brands of progestogen only contraceptive pills.  Noriday should be available again at the end of September, and Norgeston at the end of October.  There are no current issues with the supply of desogestrel (Cerazette). 



Shortage of Sayana Press

August 23, 2019

Pfizer, the sole supplier of Sayana Press (medroxyprogesterone acetate 104mg) in the UK,  have informed the Department of Health and Social Care that due to  manufacturing delays, Sayana Press will be out of stock until at least the end of 2019.

Depo-Provera (medroxyprogesterone acetate 150mg) is currently available and able to support the market during this time, should clinicians deem a switch appropriate.


23-08-2019 HRT Supply Issues

Please see here for information on HRT supply issues


Shortage of Loestrin 20 and 30

There is a current manufacturing problem with Loestrin 20 and 30, and there is no date for when this will be resolved.  The Faculty of Sexual and Reproductive Healthcare recommend that a 30mcgEE/NET COC (Ovranette®/Microgynon®/Rigevidon®) can be considered first line CHC. If this is not tolerated, there is not clear evidence to inform a recommendation favouring any one 20/30mcg EE COC over any other based on progestogen content.


British Menopause Society update on HRT supply shortages 09/08/2019

In response to the recent reports of HRT shortages, the British Menopause Society has produced an update on the current availability of HRT products. This provides guidance to BMS members, clinicians and patients who may be experiencing difficulties in obtaining HRT supplies. Please see here


Sunscreen ACBS guidance

Please note that the ACBS criteria for supplying sunscreen on prescription has been updated in the August Drug Tariff.

This replaces the old wider criteria and means that more patients will have to be advised to self-care as prescribers would be breaching their terms of service if they prescribed for patients not considered "severe".

The formulary has been updated to reflect this. Please see here


Emerade (adrenaline) Syringes- Medicines defect information

Bausch & Lomb UK limited has informed health care professionals of a risk of Emerade product failing to deliver a dose of adrenaline from the syringe due to blockage of the needle.Patients and their carers, who have been supplied with an Emerade device should  always carry two in-date adrenaline autoinjectors with them at all times. For more information please refer to medicines defect information.


Important drug supply issue affecting Salbutamol 2mg/5ml syrup

For patients who do not have sufficient supplies to last until early August, clinicians should consider prescribing alternative options during this time including unlicensed supplies of Salbutamol 2mg/5ml syrup. Clinicians will need to work with local pharmacies to understand more about the specific unlicensed products that can be sourced. Clinicians should refer to the UKMI memo for further advice if an unlicensed supply of Salbutamol 2mg/5ml syrup is considered unsuitable.


FreeStyle Libre®

FreeStyle Libre® is AMBER on the Dorset formulary and therefore, following secondary care initiation, may be prescribed in primary care. 



Pfizer Epanutin® (phenytoin) 30mg/5ml oral suspension will be out of stock from the week commencing 10 June 2019 until late July 2019.

DHSC have published the following documents: 

Re: Interim supply arrangements for Epanutin® (phenytoin) 30mg/5ml oral suspension to mitigate supply disruption

Supply Disruption Alert - Epanutin® (phenytoin) 30mg/5ml Oral Suspension – Supply Disruption

Epanutin® PIL and SPC

DILANTIN® PIL and Monograph




Information on supply issues for diamorphine and Microgynon 30® has been uploaded


08th May 2019 - Flu season has ended

Please see details here.

Guidance documents can be found here for out of season influenza prescribing. Alternatively, search the term "fluoos" is the search bar.



Epanutin® 50 mg Infatabs (phenytoin)  temporary supply issue

 Please see here for details on the supply issues affecting Epanutin 50mg Infatabs. 


Labetalol shortage of supply

Please see here for details on the supply issues affecting labetalol tablets.



Levomepromazine shortage of supply

Please see here for details on the supply issues affecting levomepromazine solution for injection. 


Fluoroquinolone Antibiotics -  MHRA Drug Safety Update 

Please see here for the update published 21/03/2019. It includes new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects


Loss of formulary mobile application 

The NetFormulary mobile application will no longer be available for use in Dorset as of May 2019.

This decision was based on the use of the application throughout Dorset, the increased access to technology for mobile healthcare teams and the functionality of the application and cost. This decision was approved by the Dorset Medicines Advisory Group of which clinicians from primary and secondary care are members.

 It is recommended that if you wish to access the formulary from your mobile phone, then to use the internet browser and use the mobile website:




Metoprolol shortage of supply 

Please see here for details on the intermittent supply issues affecting metoprolol 50mg and 100mg. This document provides suggestions for alternative agents and management options. 



Future availability of Adalat® (nifedipine) products

Please see here for details on the supply of Adalat® - There will be some out of stock periods for some preparations and long-term discontinuations.




The Dorset Opioid Prescribing for Chronic Pain: Resource Pack is now avalible

This is available on the front page of the formulary and can be found in chapter 04.07.02 (Opioid analgesics) in the links section at the bottom of the page.  

Alternatively, see here.


30/01/2019 Shortage of Carbagen® (carbamazepine) tablets

There is a shortage of Carbagen® IR tablets and PR tablets. This shortage is expected to last until mid/late 2019.

Please see the SPS information here for further details. 


10/01/2019 - Clexane® 40mg (enoxaparin) not available. Inhixa® biosimilar available 

Clexane® 40mg is currently unavailable. This shortage is expected to last until the end of February 2019. The biosimilar enoxaparin 40mg (Inhixa®) is currently available

Information on patient administration for Inhixa® is available here and also can be found under the formulary entry. 


31st December 2018 - Flu season has begun. 

Please see details here


 Epipen Latest News 03/12/2018

Update on Protocol on Dispensing of Adrenaline Auto-Injectors, 150microgram applying from 29th November 2018 


Temporary shortage of Bricanyl Turbohalers - refer to shortage memo


Epipen Latest News 13/11/2018

Revised - INTERIM PROTOCOL ON DISPENSING OF ADRENALINE AUTOINJECTORS, 150microgram applying from 5 November 2018 until further notification

Pharmacy and Dispensing Practice Q&A regarding EpiPen and EpiPen Junior Supply issue


Epipen Latest News 19/10/2018

EpiPen 150 Microgram Validation Protocol

AAI Q&As for Pharmacies and Dispensing Practices 16 10 2018

List of Jext AAIs with extended expiry dates


Epipen Latest News 15/10/2018

Adrenaline for anaphylaxis kits - a reminder to Health Care Professionals

Update: EpiPen and EpiPen Junior (adrenaline auto-injector devices) – Supply Disruption 15/10/2018

Letter to all patients/users of Junior Epipen (shared through GPs) 15/10/2018


The Department of Health and Social Care (DSHC) has clarified that although the expiry dates for the Epipen junior will not be extended, the following paragraph in the CAS alert (page 5) applies to all adrenaline auto injectors:

Whilst at present it is believed careful management of existing supply will avoid the need to use expired devices other than for batch numbers where it is known to be safe to do so, patients should be advised not to dispose of their expired devices until they have replaced them. This is because AAIs will not actively cause harm if used after expiry but they may be less effective at treating the anaphylactic episode as the potency of the adrenaline gradually reduces (and is also dependent on the conditions they were stored in). It is still preferable to use a device even if it has expired, rather than no device at all, if an in-date device is not available. 


Since the new Dorset CCG website has gone live, we are aware that some hyperlinks on the formulary are not behaving as expected. If you come across a broken hyperlink, please use the feedback tab on this website to let us know. We will then contact you with the information you require and fix the hyperlink. 


May 2018 MHRA Alert: Affected test strips, manufactured by Roche Diabetes Care, may give increased strip error messages prior to dosing with blood and in some cases may give false high or low readings, which may be hard to detect.  Affected lots include:


• 497392 

• 497391 

• 496915 

• 496809 

• 496802 

• 496807 


• 497344 

• 497392 

• 476597 

• 476646 
Accu-Chek Performa Nano mmol Kit. [Please note that the FSN only applies to the pack of Performa 10 test strips contained within the kit]
• 10153116 

• 10153114

• 10153115

• 10153112 

• 10153111


April 2018- Based on the latest information GPs can now order Hepatitis B vaccines. Please see the letter regarding the planned phase return of stock and the latest PHE Guidance for more information. Practices should be aware that Hepatitis B, for travel, is not remunerated by the NHS as part of additional services - please see our policy for overseas travel advice for more detail.


Medicines Safety Update: New measures to avoid valproate exposure in pregnancy

Valproate for epilepsy, bipolar or migraine must not be used in any woman or girl able to have children unless the conditions of a new pregnancy prevention programme are met. The programme is designed to ensure that patients are made fully aware of the risks and the need to avoid becoming pregnant. Elements of the programme include:

  • an assessment of each patient's potential for becoming pregnant,
  • pregnancy tests before starting and during treatment as needed,
  • counselling about the risks of valproate treatment and the need for effective contraception throughout treatment,
  • a review of ongoing treatment by a specialist at least annually,
  • introduction of a new risk acknowledgement form that patients and prescribers will go through at each such annual review to confirm that appropriate advice has been given and understood.

NEW: Temporary safety measures have been introduced for Esmya following reports of serious liver injury in women using the medicine for uterine fibroids. The following actions are required:

  • Do not initiate new treatment courses of Esmya, including in women who have completed one or more treatment courses previously
  • Perform liver function tests at least once a month in all women currently taking Esmya.
  • Check transaminase levels immediately in current or recent users of Esmya who present with signs or symptoms suggestive of liver injury (such as nausea, vomiting, malaise, right hypochondrial pain, anorexia, asthenia, jaundice).

To view the full CAS Alert click here.


The NEW Stoma additional products savings guidance is now available here


Defect with Buccolam oral syringes

Translucent cap may remain attached to syringe - parents and carers advised to inspect the syringe before use. For more information, refer to European Medicines Agency website


There is currently a supply problem with generic 50mg bicalutamide tablets which is expected to be resolved by the end of January 2018. GPs are requested to issue a 1 month prescription for the Casodex brand in the interim as this remains available at present.


NEW: Influenza Season 2017/18: Use of antiviral medicines.

With surveillance data indicating an increase in influenza cases in the community. GPs and other prescribers working in primary care may now prescribe antiviral medicines for the prophylaxis and treatment of infleunca at NHS expense.


NEW: FluOOS - Flu Out of Season Prescribing Protocols, Community Claim Forms, Invoice Templates and Patient Specific Direction (PDS) documents are all now published on the CCG internet pages and under the influenza chapter 05.03.04 of the Dorset Formulary. Search fluOOS to quickly find the relevant information.

news NEW: Guidance from the Department of Health regarding Hepatitis A : July 2017    
news NEW: In Focus Document for eRD can be found here    
news NEW: Stoma additional products formulary and guidance for prescribers Guidelines for the prescribing of Stoma additional products in Primary Care    
news UPDATED April 2017: Updated statement regarding the prescribing of sterile dressing packs in primary care.    

NEW - Dorset letter to decline prescribing

news Now available : Acne Vulgaris - primary care treatment pathway     
news Please see updated : Shared care guidelines for prescribing buccal midazolam (buccolam® or epistatus ®) in adults    
news Summary of DMAG recommendations January 2017 AVAILABLE HERE    
news Keep taking the tablets for January 2017 now published see link here    
news See letter on : Levetiracetam containing products 100 mg/mL oral solution presentations: Risk of medication errors associated with overdose here    
news Creon 40,000 UPDATE:available in limited quantities therefore should be restricted to those patients requiring more than 100,000 lipase units per meal or in those on lower doses where it is necessary to reduce pill burden    
news Dry Eye Pathway - Now available     
news DMAG November 2016 - Summary of recommendations can be accessed HERE    
news Influenza Season 2016/17: Use of Antiviral Medicines, new information is available HERE    
news Keep Taking the Tablets - November and December 2016 edition AVAILABLE HERE    
news Dorset Guidance on Prescribing for Overseas Travel AVAILABLE HERE    
news New - A Frequently Asked Questions regarding Low Molecular Weight Heparins document is now available    
news December 2016 - Updated Shared Care Guideline is now available for Low Molecular Weight Heparins.     
news Updated Urinary incontinence preferred products list ( as endorsed by Dorset CCG for acceptance on the pan Dorset formulary ) AVAILABLE HERE    
news The Central Alert System (CAS) have issued the following information : NHS providers are warned of the risk of severe harm and death if an insulin needle and syringe is used to administer insulin withdrawn directly from a pen device or replacement cartridge. This alert asks providers to ensure staff have access to appropriate equipment and training for administering insulin using a pen device. see link here for further information     
news Summary of Urinary Incontinence Ammendments to formulary 2016  
news October 2016 Edition of Keep Taking the Tablets is available here     
news DMAG - Summary of recommendations September 2016 Available here     
news NEW : statement on the prescribing of sterile dressing packs in primary care available here     
news September Keep Taking the Tablets is now AVAILABLE HERE    
news DMAG - July 2016 Summary of recommendations is now available here    
news For information : Fentanyl sublingual tablets -Recivit® - have been withdrawn from the UK market     
news NEW : Urticaria Pathway    
news NEW : Primary care treatment of DVT (with NOAC) pathway Available here     
news DOAC cards - Electronic version of Direct Oral Anticoagulant (DOAC) alert card is now available HERE    
news New : Guidelines outlining the duty of care regarding drugs recommended by outpatient clinics avaiable here    
news July 2016 Edition of Keep Taking the Tablets is now available here    
news Discontinuation of Orphenadrine - please see chapter 4 section 9.2 for additional information     
news Recent surveillance data from Public Health England indicates that circulation of influenza in the community has returned to baseline levels. GPs and other prescribers working in primary care should no longer prescribe antiviral medicines for the prophylaxis and treatment of influenza on an FP10 prescription form. See CAS alert for further information     
news Controlled Drugs Update June 2016 Newsletter is available Here    
news June 2016 Edition of Keep Taking the Tablets is now available :See here     
news TRUEyou: Warning that a small number of batches may give incorrect low blood glucose results. People who have the affected batches should return them to the manufacturer Safety alert for some batches of TRUEyou test strips    
news DMAG Annual Report 2015 / 2016 is now available HERE    
news DMAG - May 2016 Recommendation Summary is now available here    
news Update : Climagest ® and Climavel ® have both been discontinued . (June 2016)    
news Provision of IUD devices (intrauterine devices) fitted in Dorset Acute Hospitals and Community Services There is provision in the contracts for the funding of IUDs fitted by Obstetrics / Gynaecology and Family Planning Services in Dorset Trusts. Therefore under no circumstances should women be referred to their own GPs for a prescription (for an intrauterine device) to bring into the allocated Trust or Service for fitting.     
news May 2016 Edition of Keep Taking the tablets is now available here    
news A batch of Epistatus (midazolam) 10mg in 1ml Oromucosal Solution (Special Products Limited) is being recalled due to the wrong size of neck adaptor in some bottles, meaning the oral syringes supplied will not fit. Further details are available by clicking on the link. Note Buccolam® syringes are unaffected. Epistatus batch recall    
news The April 2016 edition of Keep Taking the Tablets is now available via this link     
news Prescriptions for Haloperidol 50mg/1ml ampoules (depot injection for schizophrenia) have been generated in error, when it had been intended for Haloperidol 5mg/1mlsolution ampoules (for nausea and vomiting) to be prescribed. See link for additional information     
news The Department of Health has issued a letter warning of increased levels of influenza virus activity and providing advice round the use of anti-viral medication. Full details are available by clicking on the link. (DoH Letter)    
news There are potential shortages of Insuman Basal and Insuman Comb 25 as a result of manufacturing problems. Advice on managing patients using these products is contained in a letter from the manufacturer. Supply issues are expected to be resolved by July 2016. Letter from Sanofi to healthcare professionals    
news For GPs - there is a free workshop available on "Optimising the use of Antipsychotic medication and non-pharmacological treatment for people with dementia" . For further information pleaee email     
news Prescribers are asked to be aware of potential shortages in supply of pioglitazone and should note advice from UK Medicines Information UKMI guidance around pioglitazone shortages    
news UPDATE : There has been joint statement from the BNF, UKMI and NPPG following the identification of dosing errors in BNF 70 and the new edition of the BNF for Children 2015-2016. To view this statement go to    
news It has been recognised nationally that the recently distributed editions of the BNF70 and the cBNF 2015-16, contain a number of errors. We encourage all prescribers to use the previous edition of the BNF (editions 68/69) A list of errors identified to date can be found at :BNF link here     
news NEW - Information regarding Delaying menstruation during holidays    
news Dorset Medicines Advisory Group (DMAG) - Recommendation summary for May 2015 available here    
news Dorset Medicines Advisory Group (DMAG) annual report for 2014 / 2015 is available to view via this link    
news New NOAC's in a nutshell . a concise guide    
news New guidance available : for prescribing contraceptives for girls under 16 years    
news Immunosuppressants - From the middle of April, the Renal department at Dorset County Hospital will routinely stop giving/sending FP10’s to patients to obtain their immunosuppression from their local community Pharmacy as they will be going through a homecare provider. If a patient needs an urgent dose change or supply, FP10s will still be used. The drugs this will mainly affect are tacrolimus (Adoport), mycophenolate mofetil, mycophenolic acid (Myfortic), sirolimus (Rapamune) and ciclosporin (Neoral). For any queries please go to chapter 8.2.2 Corticosteroids and other immunosupressants for contact details.     
news *NEW* Updated version of primary care antibiotic guideline available (link)    
news The Dorset Formulary is now available as a FREE app for both iOS and Android and can be downloaded via WiFi or 3G. Please note that the linked files, i.e. commissioning statements and shared care guidance must be downloaded via a WiFi connection (due to potential device data charges the downloaded files are switched off over 3G). A brief guide can be found here    
news To ensure that the Lyrica® pain patent is not infringed, all prescriptions for pregabalin for pain indications must be prescribed by brand. Link to NHS England guidance    
news Summary of recommendations from the January 2015 meeting of Dorset Medicines Advisory Group    
news Patient safety alert on harm from use of low molecular weight heparins when contraindicated: Stage One warning from NHS England    
news The most recent surveillance data indicate that there is now a substantial likelihood that people presenting with an influenza-like illness are infected with an influenza virus. GPs may now prescribe at NHS expense, antiviral medicines for the prophylaxis and treatment of influenza, in accordance with NICE guidance. Refer to advice from the Chief Medical Officer.    
news Class 2 medicines recall (action within 48 hours): Recall of all oral diclofenac presentations with legal status ‘P’ Tablets containing diclofenac will be available only as a Prescription Only Medicine (POM) from 15th January 2015. Topical formulations containing diclofenac will continue to be available without a prescription.     
news ALL HEALTHCARE PROFESSIONALS NHS England has published a Patient Safety Alert around the risks of serious harm from accidental ingestion of potassium permanganate solutions. LINK    
news MHRA Drug Safety Update (December 2014). Link    
news For up to date information on GSK shortages, please check via following link GSK'S medicines and vaccines supply availability    
news Some GSK steroid-containing creams will be limited during November and December 2014 (e.g. Betnovate, Dermovate, Eumovate, Trimovate etc). Generic versions of betamethasone, clobetasol and clobetasone ointment are available, although supplies may be limited. Avoid using clobetasone CREAM during supply issues. Refer to formulary for alternatives (chapter 13) Dorset Dermatology Formulary    
news MHRA Drug Safety Update Oct 14: Interferon, Dexamethasone, Basiliximab, new Drug-Driving offence